$2.15 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 113 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AFAM | Exit | ALMOST FAMILY INC | $0 | – | -13,200 | -100.0% | -0.01% | – |
ALKS | Exit | ALKERMES PLC | $0 | – | -11,000 | -100.0% | -0.02% | – |
LHCG | Exit | LHC GROUP INC | $0 | – | -19,087 | -100.0% | -0.02% | – |
MYGN | Exit | MYRIAD GENETICS INC | $0 | – | -18,777 | -100.0% | -0.02% | – |
ILMN | Exit | ILLUMINA INC | $0 | – | -8,399 | -100.0% | -0.03% | – |
WCRX | Exit | WARNER CHILCOTT PLC IRELAND | $0 | – | -34,543 | -100.0% | -0.03% | – |
GTIV | Exit | GENTIVA HEALTH SERVICES INC | $0 | – | -77,839 | -100.0% | -0.04% | – |
GILD | Exit | GILEAD SCIENCES INC | $0 | – | -35,000 | -100.0% | -0.08% | – |
RAD | Exit | RITE AID CORP | $0 | – | -700,000 | -100.0% | -0.09% | – |
MRGE | Exit | MERGE HEALTHCARE INC | $0 | – | -688,510 | -100.0% | -0.12% | – |
AMED | Exit | AMEDISYS INC | $0 | – | -233,066 | -100.0% | -0.13% | – |
Exit | MANNKIND CORPnote 5.750% 8/1 | $0 | – | -2,500,000 | -100.0% | -0.13% | – | |
TTPH | Exit | TETRAPHASE PHARMACEUTICALS I | $0 | – | -554,898 | -100.0% | -0.18% | – |
VCRA | Exit | VOCERA COMMUNICATIONS INC | $0 | – | -273,858 | -100.0% | -0.19% | – |
ATRC | Exit | ATRICURE INC | $0 | – | -630,000 | -100.0% | -0.28% | – |
ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -13,893,465 | -100.0% | -0.30% | – |
MDRX | Exit | ALLSCRIPTS HEALTHCARE SOLUTN | $0 | – | -619,360 | -100.0% | -0.38% | – |
ARAY | Exit | ACCURAY INC | $0 | – | -1,420,000 | -100.0% | -0.38% | – |
SGEN | Exit | SEATTLE GENETICS INCput | $0 | – | -300,000 | -100.0% | -0.44% | – |
IART | Exit | INTEGRA LIFESCIENCES HLDGS C | $0 | – | -258,044 | -100.0% | -0.45% | – |
ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -1,629,833 | -100.0% | -0.63% | – |
BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -247,000 | -100.0% | -0.65% | – |
HUM | Exit | HUMANA INC | $0 | – | -188,000 | -100.0% | -0.75% | – |
ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -1,067,115 | -100.0% | -0.91% | – |
HCA | Exit | HCA HOLDINGS INC | $0 | – | -553,020 | -100.0% | -0.94% | – |
CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -306,018 | -100.0% | -0.97% | – |
CYTK | Exit | CYTOKINETICS INC | $0 | – | -1,779,622 | -100.0% | -0.97% | – |
HTWR | Exit | HEARTWARE INTL INC | $0 | – | -225,167 | -100.0% | -1.01% | – |
STJ | Exit | ST JUDE MED INC | $0 | – | -525,000 | -100.0% | -1.13% | – |
CTRX | Exit | CATAMARAN CORPcall | $0 | – | -550,000 | -100.0% | -1.26% | – |
NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -2,939,741 | -100.0% | -1.60% | – |
OPTR | Exit | OPTIMER PHARMACEUTICALS INC | $0 | – | -3,025,829 | -100.0% | -2.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
CENTENE CORP DEL | 33 | Q2 2024 | 3.3% |
BIOCRYST PHARMACEUTICALS INC | 32 | Q2 2024 | 2.2% |
MOLINA HEALTHCARE INC | 27 | Q2 2024 | 1.7% |
BROOKDALE SR LIVING INC | 26 | Q2 2024 | 2.2% |
EHEALTH INC | 25 | Q3 2020 | 2.0% |
INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
DECIPHERA PHARMACEUTICALS IN | 24 | Q1 2024 | 2.0% |
MYLAN NV | 23 | Q3 2020 | 6.2% |
PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-09-17 |
3 | 2024-09-12 |
N-PX | 2024-08-29 |
13F-HR | 2024-08-14 |
4 | 2024-07-17 |
4 | 2024-07-15 |
4 | 2024-07-11 |
4 | 2024-06-14 |
4 | 2024-06-03 |
13F-HR | 2024-05-15 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.